ArticleAmerican journal of cancer research2020
Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Diet, Microbes, and Cancer Across the Tree of Life: a Systematic Review.Current nutrition reports · 2022Pooled it
- The Application of High-Throughput Technologies for the Study of Microbiome and Cancer.Frontiers in genetics · 2021Pooled it
- Trimethylamine-producing microbe Bacillus megaterium KCTC 3007 promotes antitumor immunity in endometrial cancer via type I interferon response pathways.Microbiome · 2026Article
- The Microbiota-Diet-Immunity Axis in Cancer Care: From Prevention to Treatment Modulation and Survivorship.Nutrients · 2025Review
- Mung Bean Peptides Alleviate Dextran-Sulfate-Sodium-Induced Colitis Symptoms in Mice by Protecting the Intestinal Mechanical Barrier and Regulating Gut Microbiota.Foods (Basel, Switzerland) · 2025Article
- Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota.Journal of nanobiotechnology · 2025Article
- Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer.Frontiers in pharmacology · 2025Article
- Chitosan-coated probiotic nanoparticles mitigate acrylamide-induced toxicity in the Drosophila model.Scientific reports · 2024Article
- The Anti-Inflammatory Effect of a Probiotic Cocktail in Human Feces Induced-Mouse Model.Inflammation · 2023Article
- Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications.Signal transduction and targeted therapy · 2023Review
- Bacterial infection promotes tumorigenesis of colorectal cancer via regulating CDC42 acetylation.PLoS pathogens · 2023Article
- Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients.Frontiers in cellular and infection microbiology · 2023Article
- Association between Probiotics and Modulation of Gut Microbial Community Composition in Colorectal Cancer Animal Models: A Systematic Review (2010-2021).The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Review
- Dynamic Population of Gut Microbiota as an Indicator of Inflammatory Bowel DiseaseIranian biomedical journal · 2022Article
- Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.International journal of molecular sciences · 2022Review
- Comparative Insights into the Skin Beneficial Properties of ProbioticBioMed research international · 2022Article
- Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.Frontiers in immunology · 2022Review
- Harness the functions of gut microbiome in tumorigenesis for cancer treatment.Cancer communications (London, England) · 2021Review
- The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities.Current oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32368393PMC7191089W3022723964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.